Multi-strategy convergence in Biohaven acquisition
The guest highlighted Biohaven as a prime example of a highly profitable setup where merger arbitrage, a spin-off, and insider buying converged.
The argument
Pfizer acquired Biohaven for its migraine pipeline but spun off the remaining pipeline into a new entity funded with cash. The guest identified value in both the merger spread and the cash-backed spin-off, which was further validated by unusual insider buying just before the deal closed.
The thesis, stress-tested
✓ What validates it
- ✓Successful spin-off of the non-migraine pipeline
- ✓Insiders continuing to buy shares of the spun-off entity post-transaction
▸ Risks discussed
- ▸Spin-off pipeline assets failing to achieve clinical or commercial success
- ▸Merger failing to close at the last minute
Hear it yourself
"In this episode, Asif shares his evolution from traditional value investing to a diversified event driven strategy that includes merger arbitrage, spinoffs, buybacks, insider activity, and more."
00:00 / 00:14
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE